Placebo influences on dyskinesia in Parkinson's disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1531-8257|23|5|700-707

ISSN： 0885-3185

Source： MOVEMENT DISORDERS, Vol.23, Iss.5, 2008-04, pp. : 700-707

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Possible Mechanisms Involved in Subthalamotomy-Induced Dyskinesia in Patients with Parkinson's Disease

By  

Stereotactic and Functional Neurosurgery, Vol. 91, Iss. 5, 2013-06 ,pp. : 323-327

Karger

Access to resources Recommend Favorite

Coffee consumption and risk of levodopa‐induced dyskinesia in Parkinson's disease: The FRAGAMP study

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 13, 2015-11 ,pp. : 1854-1856

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 9, 2015-08 ,pp. : 1267-1271

John Wiley & Sons Inc

Access to resources Recommend Favorite

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 6, 2015-05 ,pp. : 788-795

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 7, 2015-06 ,pp. : 912-918

John Wiley & Sons Inc

Access to resources Recommend Favorite